Improving assessment of endometrial cancer using genomic profiling and surgical methods
Official title: Improving Endometrial Cancer Assessment by Combining the New techniqUe of GENomic Profiling With Surgical Extra uterIne disEase Assessment
Run by University Hospital, Gasthuisberg · NCT06354738 · Data updated 2026-11-12
This study is testing if combining genetic testing with surgery can help doctors better understand and treat endometrial cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 1000 (estimated) |
| Sponsor | University Hospital, Gasthuisberg Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Leuven) |
| Status | Recruiting |
| Started | January 16, 2023 |
| Main results expected | November 1, 2028 |
| Study ends | November 1, 2028 |
| Registry record updated | April 17, 2024 |
| Trial ID | NCT06354738 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women aged 18 and older who are newly diagnosed with endometrial cancer, regardless of disease stage or histotype.
✕Probably not a fit
Patients with a history of pelvic or para-aortic lymph node dissection, previous pelvic radiotherapy, or those undergoing neoadjuvant chemotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance the assessment of endometrial cancer by integrating genomic profiling with surgical evaluation of extra uterine disease. It is a multicenter interventional study that seeks to correlate the stage of endometrial cancer with its molecular subgroups, thereby guiding surgical treatment and staging. The researchers will evaluate the association between molecular classification and disease stage, as well as its impact on prognosis. This approach addresses the limitations of current pre-operative risk assessments, which often lead to inaccurate staging and treatment decisions.
Why it matters
Potential benefit: If successful, this study could lead to more accurate staging and tailored treatment for patients with endometrial cancer, improving outcomes.
How similar studies have gone: Other studies have shown promise in using genomic profiling for cancer assessment, suggesting that this approach may lead to significant advancements in treatment strategies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained before any screening procedures * Women ≥ 18 years * First diagnosis of EC, all disease stages and all histo-types Exclusion Criteria: * Participant has a history of pelvic or para-aortic lymph node dissection or sampling, previous pelvic (and/or para-aortic) radiotherapy, previous neoadjuvant chemotherapy * Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol * Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Study
Where it's running
-
UZ Gasthuisberg, Katholieke Universiteit Leuven
Leuven, Belgium Recruiting
Study contacts
- Principal investigator: Frédéric Amant, MD, PhD — UZ Leuven Gasthuisberg
- Study coordinator: Frédéric Amant, MD, PhD
- Email: frederic.amant@uzleuven.be
- Phone: +3216342194
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized navigation to support rural and Black women with endometrial cancer
This pilot tests a tailored patient-navigation program to help rural and Black patients with endometrial cancer access care and services.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Liquid biopsy screening for early endometrial cancer in regional China
A non-invasive blood test using cell-free DNA is being tested to see if it can detect early endometrial cancer and tell apart benign from malignant uterine lesions.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.